Association and clinical implication of the USP10 and MSH2 proteins in non‑small cell lung cancer

Zeng,Zhi; Li,Dan; Yu,Tao; Huang,Yabing; Yan,Honglin; Gu,Lijuan; Yuan,Jingping

doi:10.3892/ol.2018.9702

Association and clinical implication of the USP10 and MSH2 proteins in non‑small cell lung cancer

Authors:
- Zhi Zeng
- Dan Li
- Tao Yu
- Yabing Huang
- Honglin Yan
- Lijuan Gu
- Jingping Yuan
View Affiliations

Affiliations: Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Integrated Traditional Chinese and Western Medicine Ward, Oncology Department, Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China, Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: November 15, 2018 https://doi.org/10.3892/ol.2018.9702
Pages: 1128-1138
Copyright: © Zeng et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ubiquitin‑specific protease 10 (USP10) is involved in a number of biological processes by stabilizing several proteins, which have been implicated in multiple stages of tumorigenesis and progression. Previous studies have indicated that USP10 stabilizes and deubiquitinates MutS homolog 2 (MSH2) in in vitro and in vivo models. The level of MSH2 protein has been positively correlated with that of the USP10 protein in a panel of lung cancer cell lines. Furthermore, depletion of USP10 in lung cancer cells causes decreased apoptosis and increased cell survival upon treatment with DNA‑damaging agents. However, the expression and clinical implication of USP10 protein in lung cancer tissues is not clear. Additionally, whether the level of MSH2 protein is positively correlated with that of the USP10 protein in lung cancer tissues also remains unresolved. Therefore, USP10 protein expression was detected in 148 human non‑small cell lung cancer (NSCLC) and 139 non‑cancerous lung tissues using immunohistochemistry, whereas mRNA was investigated by Gene Expression Omnibus dataset and The Cancer Genome Atlas database analyses. It was identified that USP10 protein expression was significantly downregulated in NSCLC tissues compared with in normal lung tissues (P<0.05). However, no significant difference in USP10 mRNA expression between the two tissues was identified. In addition, a positive correlation was observed between the USP10 and MSH2 proteins in NSCLC tissues (P<0.05). However, the clinicopathological features and survival analysis indicated that the USP10 and MSH2 proteins were not associated with clinical features, including age, sex, tumor size, Tumor‑Node‑Metastasis stage and tumor cell differentiation, along with the prognosis of NSCLC. Collectively, these results suggest that downregulation of USP10 protein serves an important function in the tumorigenesis of NSCLC, and the level of USP10 protein is positively correlated with that of MSH2 protein in NSCLC tissues, which may indicate that USP10 also stabilizes the MSH2 protein in patients with lung cancer.

View Figures

View References

1	Hicke L and Dunn R: Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol. 19:141–172. 2003. View Article : Google Scholar : PubMed/NCBI
2	Love KR, Catic A, Schlieker C and Ploegh HL: Mechanisms, biology and inhibitors of deubiquitinating enzymes. Nat Chem Biol. 3:697–705. 2007. View Article : Google Scholar : PubMed/NCBI
3	Yuan J, Luo K, Zhang L, Cheville JC and Lou Z: USP10 regulates p53 localization and stability by deubiquitinating p53. Cell. 140:384–396. 2010. View Article : Google Scholar : PubMed/NCBI
4	Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK and Bernards R: A genomic and functional inventory of deubiquitinating enzymes. Cell. 123:773–786. 2005. View Article : Google Scholar : PubMed/NCBI
5	Soncini C, Berdo I and Draetta G: Ras-GAP SH3 domain binding protein (G3BP) is a modulator of USP10, a novel human ubiquitin specific protease. Oncogene. 20:3869–3879. 2001. View Article : Google Scholar : PubMed/NCBI
6	Liu J, Xia H, Kim M, Xu L, Li Y, Zhang L, Cai Y, Norberg HV, Zhang T, Furuya T, et al: Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell. 147:223–234. 2011. View Article : Google Scholar : PubMed/NCBI
7	Pan L, Chen Z, Wang L, Chen C, Li D, Wan H, Li B and Shi G: Deubiquitination and stabilization of T-bet by USP10. Biochem Biophys Res Commun. 449:289–294. 2014. View Article : Google Scholar : PubMed/NCBI
8	Yang Q, Ou C, Liu M, Xiao W, Wen C and Sun F: NRAGE promotes cell proliferation by stabilizing PCNA in a ubiquitin-proteasome pathway in esophageal carcinomas. Carcinogenesis. 35:1643–1651. 2014. View Article : Google Scholar : PubMed/NCBI
9	Lin Z, Yang H, Tan C, Li J, Liu Z, Quan Q, Kong S, Ye J, Gao B and Fang D: USP10 antagonizes c-Myc transcriptional activation through SIRT6 stabilization to suppress tumor formation. Cell Rep. 5:1639–1649. 2013. View Article : Google Scholar : PubMed/NCBI
10	Niu J, Shi Y, Xue J, Miao R, Huang S, Wang T, Wu J, Fu M and Wu ZH: USP10 inhibits genotoxic NF-κB activation by MCPIP1-facilitated deubiquitination of NEMO. EMBO J. 32:3206–3219. 2013. View Article : Google Scholar : PubMed/NCBI
11	Zeng Z, Wu HX, Zhan N, Huang YB, Wang ZS, Yang GF, Wang P and Fu GH: Prognostic significance of USP10 as a tumor-associated marker in gastric carcinoma. Tumour Biol. 35:3845–3853. 2014. View Article : Google Scholar : PubMed/NCBI
12	Koul R, Rathod S, Dubey A, Bashir B and Chowdhury A: Comparison of 7th and 8th editions of the UICC/AJCC TNM staging for non-small cell lung cancer in a non-metastatic North American cohort undergoing primary radiation treatment. Lung Cancer. 123:116–120. 2018. View Article : Google Scholar : PubMed/NCBI
13	Zhang M, Hu C, Tong D, Xiang S, Williams K, Bai W, Li GM, Bepler G and Zhang X: Ubiquitin-specific peptidase 10 (USP10) deubiquitinates and stabilizes MutS Homolog 2 (MSH2) to regulate cellular sensitivity to DNA damage. J Biol Chem. 291:10783–10791. 2016. View Article : Google Scholar : PubMed/NCBI
14	Cao Y, Wei M, Li B, Liu Y, Lu Y, Tang Z, Lu T, Yin Y, Qin Z and Xu Z: Functional role of eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) in NSCLC. Oncotarget. 7:24242–24251. 2016.PubMed/NCBI
15	Heinen CD: Translating mismatch repair mechanism into cancer care. Curr Drug Targets. 15:53–64. 2014. View Article : Google Scholar : PubMed/NCBI
16	Kamal NS, Soria JC, Mendiboure J, Planchard D, Olaussen KA, Rousseau V, Popper H, Pirker R, Bertrand P, Dunant A, et al: MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res. 16:1206–1215. 2010. View Article : Google Scholar : PubMed/NCBI
17	Ko JC, Chiu HC, Syu JJ, Chen CY, Jian YT, Huang YJ, Wo TY, Jian YJ, Chang PY, Wang TJ and Lin YW: Down-regulation of MSH2 expression by Hsp90 inhibition enhances cytotoxicity affected by tamoxifen in human lung cancer cells. Biochem Biophys Res Commun. 456:506–512. 2015. View Article : Google Scholar : PubMed/NCBI
18	Zeng Z, Zhou Z, Zhan N, Yuan J, Ye B, Gu L, Wang J, Jian Z and Xiong X: USP10 expression in normal adrenal gland and various adrenal tumors. Endocr Pathol. 26:302–308. 2015. View Article : Google Scholar : PubMed/NCBI
19	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
20	Politi K and Herbst RS: Lung cancer in the era of precision medicine. Clin Cancer Res. 21:2213–2220. 2015. View Article : Google Scholar : PubMed/NCBI
21	Tang H and Shrager JB: CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer: A personalized molecular surgical therapy. EMBO Mol Med. 8:83–85. 2016. View Article : Google Scholar : PubMed/NCBI
22	McCloskey P, Balduyck B, Van Schil PE, Faivre-Finn C and O'Brien M: Radical treatment of non-small cell lung cancer during the last 5 years. Eur J Cancer. 49:1555–1564. 2013. View Article : Google Scholar : PubMed/NCBI
23	Santarpia M, Rolfo C, Peters GJ, Leon LG and Giovannetti E: On the pharmacogenetics of non-small cell lung cancer treatment. Expert Opin Drug Metab Toxicol. 12:307–317. 2016. View Article : Google Scholar : PubMed/NCBI
24	Deng S, Zhou H, Xiong R, Lu Y, Yan D, Xing T, Dong L, Tang E and Yang H: Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics. Breast Cancer Res Treat. 104:21–30. 2007. View Article : Google Scholar : PubMed/NCBI
25	Grunda JM, Nabors LB, Palmer CA, Chhieng DC, Steg A, Mikkelsen T, Diasio RB, Zhang K, Allison D, Grizzle WE, et al: Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM). J Neurooncol. 80:261–274. 2006. View Article : Google Scholar : PubMed/NCBI
26	Kitamura H, Kameda Y, Ito T and Hayashi H: Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. Am J Clin Pathol. 111:610–622. 1999. View Article : Google Scholar : PubMed/NCBI
27	Mori M, Kaji M, Tezuka F and Takahashi T: Comparative ultrastructural study of atypical adenomatous hyperplasia and adenocarcinoma of the human lung. Ultrastruct Pathol. 22:459–466. 1998. View Article : Google Scholar : PubMed/NCBI
28	Osanai M, Igarashi T and Yoshida Y: Unique cellular features in atypical adenomatous hyperplasia of the lung: Ultrastructural evidence of its cytodifferentiation. Ultrastruct Pathol. 25:367–373. 2001. View Article : Google Scholar : PubMed/NCBI
29	Beasley MB, Brambilla E and Travis WD: The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 40:90–97. 2005. View Article : Google Scholar : PubMed/NCBI
30	Liu H, Xu XF, Zhao Y, Tang MC, Zhou YQ, Lu J and Gao FH: MicroRNA-191 promotes pancreatic cancer progression by targeting USP10. Tumour Biol. 35:12157–12163. 2014. View Article : Google Scholar : PubMed/NCBI
31	Cai B, Ma W, Bi C, Yang F, Zhang L, Han Z, Huang Q, Ding F, Li Y, Yan G, et al: Long noncoding RNA H19 mediates melatonin inhibition of premature senescence of c-kit(+) cardiac progenitor cells by promoting miR-675. J Pineal Res. 61:82–95. 2016. View Article : Google Scholar : PubMed/NCBI
32	Guturi KK, Bohgaki M, Bohgaki T, Srikumar T, Ng D, Kumareswaran R, El Ghamrasni S, Jeon J, Patel P, Eldin MS, et al: RNF168 and USP10 regulate topoisomerase IIα function via opposing effects on its ubiquitylation. Nat Commun. 7:126382016. View Article : Google Scholar : PubMed/NCBI
33	Li D, Zeng Z, Yu T, Qin J, Wu J, Song JC, Zhou ZY and Yuan JP: Expression and clinical implication of S100A12 in gastric carcinoma. Tumour Biol. 37:6551–6559. 2016. View Article : Google Scholar : PubMed/NCBI
34	Xie KJ, He HE, Sun AJ, Liu XB, Sun LP and Dong XJ: Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy. Asian Pac J Cancer Prev. 15:2591–2596. 2014. View Article : Google Scholar : PubMed/NCBI
35	Levallet G, Dubois F, Fouret P, Antoine M, Brosseau S, Bergot E, Beau-Faller M, Gounant V, Brambilla E, Debieuvre D, et al: MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 phase 3 trial. Oncotarget. 8:4313–4329. 2017. View Article : Google Scholar : PubMed/NCBI